medigraphic.com
SPANISH

Acta Médica del Centro

ISSN 1995-9494 (Electronic)
Revista del Hospital Clínico Quirúrgico "Arnaldo Milián Castro"
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2012, Number 3

<< Back Next >>

Acta Med Cent 2012; 6 (3)

Intravitreal injections to prevent blindness due to wet type age-related macular degeneration

Pérez MEC, Rodríguez DF, Guillen BME
Full text How to cite this article

Language: Spanish
References: 8
Page:
PDF size: 20.75 Kb.


Key words:

Macular degeneration, intravitreal injections, treatment outcome.

ABSTRACT

A research on a novel treatment used in wet type age-related macular degeneration – a common cause of irreversible blindness worldwide – was conducted with the aim of raising awareness of its effectiveness according to evidence-based studies performed by prestigious health institutions. The technique is the use of intravitreal injections of lucentis (bevacizumab) and avastin (monoclonal antibodies) to neutralize the biological activity of the growth factor of the vascular endothelium and to reduce vascular permeability. The long-term post intravitreal positive effects are shown, and the possibility of using a more economical drug with similar visual results.


REFERENCES

  1. Vaughan H. Retina y tumores. En: Oftalmología General. 17 ed. México: El Manual Moderno; 2008. p. 216-17.

  2. Neira Ovalle E. Degeneración macular relacionada con la edad. En: Valenzuela Haag H, Lechuga Carreño M. Oftalmología General. Chile: Universidad de Chile, Servicio de Oftalmología; 2007. p. 123-5.

  3. Kanski JJ. Degeneración Macular Senil. En: Oftalmología clínica. 5ta ed. Madrid: Elsevier; 2006. p. 175-84.

  4. Chávez Pardo I, González Varona D, Miranda Remedios DE. Degeneración macular relacionada con la edad. AMC. 2008; (12)2: 1025-55.

  5. Arantes Tiago FE, Vinícius Paganini N, Otacílio de Oliveira MJ, Walter Yukihiko T. Bevacizumab (Avastin®) no tratamento da membrana neovascular coroidal secundária à degeneração macular relacionada à idade: relato de caso. Arq Bras Oftalmol [serial on the Internet]. 2007 dec [cited 2012 Sep 21]; 70(6): 1016-20. Available from: http://www.scielo.br/scielo.php?pid=S000427492007000600025&script=sci_arttext

  6. Asamblea Mundial de la Salud. Prevención de la ceguera y la deficiencia visual. [Internet] WHA59.25. Documento A59/12 [acceso 27 de abril de 2009]: [aprox. 3 p.]. Disponible en: https://apps.who.int/gb/ebwha/pdf_files/WHA59/A59_R25-sp.pdf.

  7. Medicamento inyectable evitaría degeneración macular. [Internet] Boston: Reuters Health; 2006 oct 5. [acceso 7 de julio de 2012]: [aprox. 1 p.]. Disponible en: http://bvs.sld.cu/aldia/veruna.php?idnews=16814&id=2&idform=2

  8. Eguía Martínez F, Río Torres M, Capote Cabrera A. Degeneración macular relacionada con la edad húmeda. En: Manual de diagnóstico y Tratamiento en Oftalmología. La Habana: Ecimed; 2009. p. 387-97.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Acta Med Cent. 2012;6